Nektar Therapeutics (NKTR) reported that partner AstraZeneca announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
MOVENTIG is part of an exclusive worldwide licence agreement between AstraZeneca and Nektar Therapeutics. MOVENTIG was developed using Nektar's oral small molecule polymer conjugate technology.
For comments and feedback contact: editorial@rttnews.com
Business News